Superworth

Acadia Pharmaceuticals free cash flow ACAD

Cash from operations less capital spending, by quarter and over the last twelve months, from 2011.

Last 12 months, to Jun 30, 2026
$145.6M
Latest quarter, Q2 FY26
$95.7M
+50% on a year earlier
Fiscal year 2025
$105.1M

Acadia Pharmaceuticals' free cash flow was $145.6M over the twelve months to Jun 30, 2026, down 22% on a year earlier.

In its latest quarter, Q2 FY26, it was $95.7M, up 50% on the same quarter a year before.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2025$105.1Mn/a
FY2024n/an/a
FY2023n/an/a
FY2022−$114Mn/a
FY2021−$126.8Mn/a
FY2020−$143.8Mn/a
FY2019−$152.3Mn/a
FY2018−$169.6Mn/a
FY2017−$218.6Mn/a
FY2016−$211.9Mn/a
FY2015−$123.9Mn/a
FY2014−$66.6Mn/a
FY2013n/an/a
FY2012n/an/a
FY2011n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q2 FY26$95.7M+50%$145.6M
Q1 FY26$28.8M+42%$113.6M
Q4 FY25−$52.7M−232%$105.1M
Q3 FY25$73.9M+17%$197.8M
Q2 FY25$63.7Mn/a$187.1M
Q1 FY25$20.3Mn/an/a
Q4 FY24$39.9M−53%n/a
Q3 FY24$63.2Mn/an/a
Q4 FY23$85.4Mn/an/a
Q4 FY22−$23.9Mn/a−$114M
Q3 FY22−$727Kn/a−$113.3M
Q2 FY22−$13.1Mn/a−$129.6M

Against its peers

Companies in Drug Manufacturers - General nearest Acadia Pharmaceuticals' size, closest first, today.

CompanyFree cash flow yield
ACADAcadia Pharmaceuticals4.3%
OGNOrganon15.7%
LQDALiquidia3.9%
ARQTArcutis Biotherapeutics1.0%
INDVIndivior Pharmaceuticals−2.7%
NRIXNurix Therapeutics13.4%
PBHPrestige Consumer Healthcare10.4%
HRMYHarmony Biosciencesn/m
KNSAKiniksa Pharmaceuticals International3.1%
LGNDLigand Pharmaceuticals2.2%
AMRXAmneal Pharmaceuticals2.0%
Peer median3.1%

Where Acadia Pharmaceuticals ranks

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Acadia Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.